Twist Bioscience Corp (TWST) Stock Price Down 6.6% on Feb 20
Shares of Twist Bioscience Corp (TWST) experienced a 6.6% drop in mid-day trading on February 20th, reaching an intraday low of $48.38 before closing at $49.07. Despite the decline, the stock remains significantly above its 52-week low. Analyst forecasts show an average price target of $50.60, indicating a potential upside from the current price, and the consensus recommendation is "Outperform."
Insider Sell: Paula Green Sells 39,404 Shares of Twist Bioscience Corp (TWST)
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp, sold 39,404 shares of the company on February 17, 2026. This transaction reduced her holdings to 126,041 shares. Twist Bioscience Corp, a synthetic DNA producer, has seen 118 insider sells and no buys over the past year, with the stock currently considered modestly overvalued based on its GF Value.
Twist Bioscience to Present at Upcoming Investor Conferences
Twist Bioscience Corporation announced that its CEO, Emily M. Leproust, and CFO, Adam Laponis, will participate in fireside chats at three upcoming investor conferences in March: the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Global Healthcare Conference. These presentations will be webcast live and archived for 30 days on the company's investor relations website.
Biotech CEO and CFO face investor questions at three March conferences
Twist Bioscience announced that its CEO and co-founder, Emily M. Leproust, Ph.D., and CFO, Adam Laponis, will participate in fireside chats at three upcoming investor conferences in March. These events include the TD Cowen 46th Annual Health Care Conference, Barclays 28th Annual Global Healthcare Conference, and Leerink Global Healthcare Conference. Webcasts of these fireside chats will be available on the company's investor relations website, with replays archived for 30 days.
Twist Bioscience to Present at Upcoming Investor Conferences
Twist Bioscience Corporation announced that its CEO, Emily M. Leproust, and CFO, Adam Laponis, will participate in fireside chats at three upcoming investor conferences in March. These conferences include the Cowen 46th Annual Health Care Conference, Barclays 28th Annual Global Healthcare Conference, and Leerink Global Healthcare Conference. Webcasts of these chats will be available on the company's investor relations website for 30 days.
Twist Bioscience to Present at Upcoming Investor Conferences
Twist Bioscience Corporation announced that its CEO, Emily M. Leproust, and CFO, Adam Laponis, will participate in fireside chats at three upcoming investor conferences in March 2026. These presentations will be webcast live and archived on the company's investor relations website for 30 days. Twist Bioscience uses its silicon-based DNA synthesis platform to serve customers in various fields, including medicine, agriculture, and industrial chemicals.
Twist Bioscience stock hits 52-week high at $51.02
Twist Bioscience (TWST) stock reached a new 52-week high of $51.02, driven by investor confidence in its growth prospects and advancements in synthetic biology, despite analysts noting the stock appears overvalued. The company reported strong Q1 2026 revenue of $103.7 million and expanded its antibody discovery services through a new licensing agreement, further highlighting its strategic developments. These achievements underscore Twist Bioscience's upward trajectory and market presence in the biotech sector.
Twist Bioscience Corporation (TWST) Stock Analysis: A Promising Play in Synthetic DNA with 16.9% Revenue Growth
Twist Bioscience Corporation (TWST) is an innovative company in synthetic DNA, showing a 16.9% revenue growth and trading near its 52-week high. Despite strong market confidence and positive analyst sentiment, the company faces profitability challenges with negative EPS and free cash flow. Investors are advised to consider its long-term growth potential in gene editing and diagnostic testing against current financial hurdles.
Twist Bioscience stock hits 52-week high at $51.02
Twist Bioscience stock has reached a new 52-week high of $51.02, reflecting strong investor confidence with 74.6% returns over six months and 54.8% year-to-date. This performance is attributed to the company's advancements in synthetic biology and expanded market presence. The company recently reported strong Q1 2026 revenues, a new licensing agreement, and shareholder approvals for director elections and executive compensation.
Twist Bioscience stock hits 52-week high at $51.02 By Investing.com
Twist Bioscience stock (TWST) recently hit a new 52-week high of $51.02, reflecting investor confidence and impressive returns. The company's growth is attributed to advancements in synthetic biology and an expanding market presence, although analysts note the stock appears overvalued relative to its Fair Value. Recent developments include exceeding revenue expectations in Q1 2026 earnings, a licensing agreement with Invenra Inc., and shareholder approval of director elections and executive compensation.
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
Twist Bioscience has entered into a licensing agreement with Invenra Inc. for its B-Body® bispecific antibody platform, becoming a co-exclusive provider of the technology. This agreement expands Twist's antibody discovery services, allowing for rapid and precise expression and discovery of complex bispecific antibody therapeutics. Twist will provide Invenra with an upfront payment of $5 million in cash and $15 million in common stock, and will also acquire an approximately 6% ownership in Invenra through a $13.8 million stock purchase.
Twist Bioscience stock hits 52-week high at $51.02
Twist Bioscience (TWST) stock reached a new 52-week high of $51.02, driven by increased investor confidence and advancements in synthetic biology. The company has shown strong returns over the past six months and year-to-date, despite analysts noting the stock appears overvalued relative to its Fair Value. Recent developments include exceeding revenue expectations in Q1 2026, a new licensing agreement, and shareholder approval of director elections and executive compensation.
Twist Bioscience Raises FY26 Revenue Forecast Exceeding Market Expectations
Twist Bioscience (TWST) shares rose by 7.51% after the company announced Q1 revenue of $103.7M, surpassing predictions, and forecast FY26 revenue between $435M to $440M, exceeding market expectations. Strategic expansions, particularly with new library preparation kits for genome sequencing, and positive analyst revisions (Baird to $50, Barclays maintaining "overweight") have boosted investor confidence and market predictions for continued growth. The company's consistent gross margins over 50% and twelve consecutive growth quarters further solidify its strong financial position and positive outlook.
Twist Bioscience licenses Invenra’s bispecific antibody platform
Twist Bioscience has entered into a licensing agreement with Invenra Inc. for its B-Body bispecific antibody platform, becoming a co-exclusive provider. The deal involves an upfront payment of $5 million cash and $15 million in Twist common stock, plus a 6% ownership stake in Invenra through a $13.8 million stock purchase. This strategic move expands Twist's antibody discovery services and aims to address the growing demand for next-generation bispecifics.
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
Twist Bioscience has announced a licensing agreement with Invenra Inc. for its B-Body® bispecific antibody platform, significantly expanding Twist's antibody discovery services. This agreement positions Twist Bioscience as a co-exclusive provider of the B-Body platform, enabling rapid, efficient, and precise expression and discovery of complex bispecific antibody therapeutics. Twist will make an upfront payment of $5 million in cash and $15 million in common stock to Invenra, and will also acquire a 6% ownership stake in Invenra through a secondary transaction.
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement
Twist Bioscience has announced a licensing agreement with Invenra Inc., making Twist a co-exclusive provider of Invenra's B-Body bispecific antibody platform. This agreement expands Twist's antibody discovery services to include a proven and scalable bispecific antibody platform, complementing its existing offerings. Twist will provide Invenra with an upfront payment of $5 million in cash and $15 million in Twist common stock, and will pay a 20% royalty on all license revenue generated.
Is Twist’s Expanded NGS Library Kit Portfolio and Higher 2026 Guidance Altering The Investment Case For Twist Bioscience (TWST)?
Twist Bioscience recently launched new NGS library preparation kits and raised its 2026 revenue guidance, impacting its investment narrative. While the product expansion supports the company's long-term growth and scalability, the core investment case still hinges on margin improvement and profitability, as the company remains loss-making. Analysts have varying expectations for Twist Bioscience's future, with some projecting significant revenue growth by 2028 and others raising concerns about execution risks and continued unprofitability.
Is Twist’s Expanded NGS Library Kit Portfolio and Higher 2026 Guidance Altering The Investment Case For Twist Bioscience (TWST)?
Twist Bioscience has launched new next-generation sequencing (NGS) library kits to enhance workflows and raised its 2026 revenue guidance to US$435 million to US$440 million. While the expanded product portfolio and increased guidance support the company's growth narrative, the core investment case still hinges on margin improvement and the company's ability to achieve profitability amidst continued losses. The article suggests investors should consider the execution risks in new markets that could keep Twist unprofitable for longer.
Insider Sell: Adam Laponis Sells 7,000 Shares of Twist Bioscience Corp (TWST)
Adam Laponis, CFO of Twist Bioscience Corp (TWST), sold 7,000 shares of the company on February 12, 2026, and now holds 130,031 shares. This sale contributes to a total of 37,379 shares sold by Laponis over the past year, with no insider purchases recorded for TWST during the same period. The stock was trading at $50 per share at the time of sale, making it modestly overvalued compared to its GF Value of $42.16.
Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 7,000 Shares
Twist Bioscience CFO Adam Laponis sold 7,000 shares of company stock for $350,000 on February 12th, reducing his direct stake by 5.11%. This follows other recent sales in January, totaling 12,738 shares generating over $566,000. Despite missing EPS estimates, Twist Bioscience exceeded revenue expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $45.88.
Twist Bioscience Corporation (NASDAQ:TWST) Given Average Rating of "Moderate Buy" by Analysts
Nine analysts have assigned Twist Bioscience Corporation (NASDAQ:TWST) an average rating of "Moderate Buy," with an average 12-month target price of $45.88. Recent analyst price target increases from Evercore and Barclays indicate positive outlooks. Despite insiders selling 24,609 shares totaling approximately $1.07 million in the past 90 days, the company's Q3 revenue of $103.7 million surpassed expectations, though EPS missed estimates.
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
Twist Bioscience has launched two new library preparation kits, the Twist TrueAmp Library Preparation Kit and the Twist PCR-Free WGS Library Preparation Kit, both powered by proprietary enzymes. These kits are designed to improve performance and accuracy for next-generation sequencing, especially with low-input or challenging samples. The goal is to facilitate clinical research by minimizing errors, maximizing coverage, and streamlining large-scale workflows.
This Insider Has Just Sold Shares In Twist Bioscience
A VP & Chief Accounting Officer at Twist Bioscience recently sold US$328k worth of stock, reducing their holding by 21%. This follows a larger sale by a co-founder in the last year, suggesting insiders might view the shares as fully valued. While insiders own a reasonable 2.1% of the company, the consistent selling without corresponding purchases raises caution for potential investors.
Aptamer Technology Integrated Into Twist’s New TrueAmp NGS Library Prep Kit
Aptamer Group plc announced that Twist Bioscience Corporation has launched its new TrueAmp Library Preparation Kit, which integrates Aptamer’s proprietary Optimer® binders for enhanced room-temperature stability. This kit is a significant advancement in next-generation sequencing (NGS) library amplification, delivering high performance and yields even from low-input or degraded samples. The partnership leverages Twist Bioscience's synthetic biology expertise and Aptamer's Optimer® binder technology to improve genomics research and clinical applications.
Twist's new DNA prep kits salvage low-quality genome samples
Twist Bioscience has introduced new DNA library preparation kits, the Twist TrueAmp Library Preparation Kit and the Twist PCR-Free WGS Library Preparation Kit. These kits are designed to enhance the quality and accuracy of genomic sequencing, especially for low-input or degraded samples, by utilizing proprietary engineered enzymes. The goal is to improve variant detection, streamline workflows, and support diverse clinical and research applications, including whole genome sequencing and targeted approaches.
This Insider Has Just Sold Shares In Twist Bioscience
Robert Werner, VP & Chief Accounting Officer at Twist Bioscience, recently sold US$328k worth of stock, representing 21% of his holding. This follows a larger sale by Co-Founder Emily Leproust of US$1.0m worth of shares. While insiders own about 2.1% of the company, the consistent selling without any purchases raises caution for potential investors.
This Insider Has Just Sold Shares In Twist Bioscience
Robert Werner, VP & Chief Accounting Officer at Twist Bioscience, recently sold US$328k worth of stock, representing 21% of his holding. This follows a larger sale by Co-Founder Emily Leproust of US$1.0m worth of shares in the past year, both transactions occurring below the current share price. While company insiders retain about 2.1% ownership, there have been no insider buys in the last twelve months, which raises caution for potential investors.
Twist Bioscience Launches Next-Generation Library Preparation Kits Powered by Proprietary Enzymes
Twist Bioscience has launched new library preparation kits, the Twist TrueAmp Library Preparation Kit and the Twist PCR-Free WGS Library Preparation Kit, designed for next-generation sequencing. These kits leverage proprietary enzymes, including a newly developed TrueAmp polymerase, to handle challenging samples and improve data quality for clinical research. The company aims to provide more accurate variant detection, robust performance from difficult samples, and user-friendly workflows for both broad whole-genome sequencing and targeted approaches.
Twist Bioscience (NASDAQ:TWST) Director Sells $105,402.00 in Stock
Twist Bioscience (NASDAQ:TWST) Director Jan Johannessen sold 2,200 shares of the company's stock for $105,402.00 on February 6th, reducing his stake by over 11%. The sale occurred after the company reported mixed quarterly results, missing EPS estimates but exceeding revenue expectations, while remaining unprofitable. Analysts currently rate TWST as a "Moderate Buy" with an average target price of $45.88.
Twist Bioscience Annual Meeting: Shareholders Elect Directors, Approve Pay and EY Auditor Ratification
Twist Bioscience (NASDAQ:TWST) held its 2026 annual meeting where shareholders elected three directors—Keith Crandell, Jan Johannessen, and Trynka Shineman Blake—approved executive compensation, and ratified Ernst & Young LLP as the auditor for fiscal 2026. A significant quorum of 91.81% of shares was represented. No stockholder questions were submitted during the Q&A session.
Twist Bioscience Shareholders Back Directors and Governance Items
Twist Bioscience's shareholders elected three Class II directors, approved executive compensation, and ratified Ernst & Young as the auditor for fiscal year 2026. This indicates strong investor support for the company's leadership and governance practices. Despite weak financial performance, the company shows strong technical momentum and a constructive earnings outlook with raised FY2026 guidance.
IQ EQ FUND MANAGEMENT IRELAND Ltd Acquires 126,260 Shares of Twist Bioscience Corporation $TWST
IQ EQ FUND MANAGEMENT IRELAND Ltd significantly increased its stake in Twist Bioscience Corporation, acquiring an additional 126,260 shares to hold 265,851 shares valued at approximately $7.48 million. This comes as Twist Bioscience lifted its guidance, citing stronger demand including AI-driven growth, leading several analysts to raise price targets. Despite recent insider sales by top executives, other institutional investors have also increased their holdings, and the company reported revenue above estimates though it remains unprofitable.
Twist Bioscience (TWST) Valuation After Q1 Beat And Raised 2026 Outlook
Twist Bioscience (TWST) reported a strong Q1 with better-than-expected revenue and raised its full-year 2026 sales outlook, contributing to a significant short-term stock rally. However, Simply Wall St's analysis suggests the company is currently overvalued with a fair value of $35.63 against a $48.12 closing price, despite showing improving gross margins and a path to EBITDA breakeven. The article also highlights potential risks including customer concentration and the need for future capital raises, while offering alternative valuation perspectives based on its P/S ratio compared to industry averages.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation announced inducement grants consisting of 114,869 equity awards (107,742 RSUs and up to 7,127 PSUs) to 52 new hires. These grants are made under the company's Amended and Restated Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to incentivize their employment. The RSUs vest over 48 months, and PSUs vest based on performance metrics to be achieved by the end of the 2027 fiscal year.
TWST: Evercore ISI Group Raises Price Target on Twist Bioscience
Evercore ISI Group has increased its price target for Twist Bioscience (TWST) to $52.00 from $42.00, while maintaining an "Outperform" rating, indicating growing analyst confidence. This adjustment follows several other positive rating updates from various firms, reflecting optimism about the company's market position and strategic advancements in synthetic biology. Twist Bioscience, operating across the Americas, EMEA, and APAC, utilizes a proprietary semiconductor-based DNA synthesis platform which enables cost-effective, high-throughput production of synthetic DNA, accelerating innovation.
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Twist Bioscience Corporation announced inducement grants totaling 114,869 equity awards, comprising 107,742 restricted stock units (RSUs) and up to 7,127 performance stock units (PSUs), to 52 newly hired individuals. These grants are considered material inducements for their acceptance of employment and are issued under Twist's Amended and Restated Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over 48 months, while the PSUs vest based on performance metrics to be achieved by the end of fiscal year 2027.
Twist Bioscience Corporation $TWST Stake Raised by Thrivent Financial for Lutherans
Thrivent Financial for Lutherans increased its stake in Twist Bioscience (NASDAQ:TWST) by 14.5% in Q3, now owning 1,463,085 shares valued at $41.17 million. This comes as Twist Bioscience reported Q1 revenue of $103.7 million, beating estimates, and raised its FY26 revenue guidance, despite an EPS miss and continued unprofitability. The company's stock rallied on the positive revenue news and upgraded guidance, though analysts remain divided on its long-term profitability and market size.
Twist Bioscience Corporation (NASDAQ:TWST) Q1 2026 Earnings Call Transcript
Twist Bioscience Corporation reported strong Q1 2026 results, marking its twelfth consecutive quarter of revenue growth, driven largely by its DNA synthesis and protein solutions segment, particularly the emerging AI-enabled discovery market. The company revised its full-year revenue guidance upwards and reiterated its commitment to achieving adjusted EBITDA breakeven in 2026, while strategically investing in commercial capabilities and digital infrastructure to accelerate future growth. The earnings call highlighted the company's differentiated semiconductor-based DNA synthesis platform, which positions it strongly in expanding serviceable markets across therapeutics, diagnostics, and applied fields.
These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results
Twist Bioscience (NASDAQ: TWST) reported better-than-expected Q1 sales of $103.70 million, an 17% year-over-year increase, causing analysts to raise their forecasts. The company also increased its fiscal 2026 sales guidance to $435 million-$440 million. Following these results, Barclays and Evercore ISI Group maintained Overweight and Outperform ratings, respectively, and increased their price targets for TWST stock.
Twist Bioscience opens Q1 2026 books, sets investor call today
Twist Bioscience Corporation (NASDAQ: TWST) announced its financial results and business highlights for the first quarter fiscal 2026, which ended December 31, 2025. The company will host a conference call and live audio webcast today at 8:00 a.m. Eastern Time to discuss these results and provide a business update for analysts and investors. Interested parties can find the detailed earnings report and registration information on the Investor Relations section of Twist Bioscience's website.
Twist Bioscience Corporation (TWST): A Bull Case Theory
This article summarizes a bullish thesis on Twist Bioscience Corporation (TWST), highlighting its silicon-based DNA synthesis technology, growing customer base, and strong financial performance with increasing revenue and gross margins. The company is poised for profitability, with full-year revenue guidance of $374–376 million and expected adjusted EBITDA breakeven by fiscal 2026, suggesting significant re-rating potential despite its current valuation.
Twist Bioscience Corp SEC 10-Q Report
Twist Bioscience Corp has released its Q3 Form 10-Q report, detailing significant financial and operational growth. The company saw a 16.9% increase in revenues to $103.7 million and improved its gross margin to 52.0%. Despite increased selling, general, and administrative expenses, the company reduced its net loss and net loss per share compared to the previous year, highlighting strategic shifts and operational efficiencies.
Why Is Twist Bioscience Stock Soaring Monday?
Twist Bioscience (NASDAQ: TWST) reported strong first-quarter 2026 results, beating sales consensus and raising fiscal year 2026 sales guidance. The company also improved its gross margin and is on track to achieve adjusted EBITDA breakeven for Q4 2026. This positive financial performance and outlook led to a significant increase in its stock price.
Twist Bioscience: Ingenious Product Still Lacks Compelling Use Cases (NASDAQ:TWST)
Twist Bioscience (TWST) reported Q1 2026 revenue of $103.7M, showing a 17% year-over-year increase, and raised its full-year guidance. While the company aims for adjusted EBITDA breakeven in Q4 2026 and expects gross margins above 52%, the author maintains a Hold rating. Concerns revolve around the incremental growth, competitive pressures, and the lack of truly compelling use cases for its innovative product, suggesting potential for cheaper entry points into the stock.
Twist Bioscience shares jump 5% after revenue tops forecasts and outlook is lifted
Twist Bioscience saw its shares jump 5% after reporting better-than-expected revenue and raising its full-year outlook. The company's fiscal first-quarter revenue reached $67.4 million, surpassing analyst estimates, driven by strong growth in its SynBio and NGS segments. Twist Bioscience also narrowed its net loss and increased its revenue projections for the 2024 fiscal year.
Twist Bioscience Corporation $TWST Shares Purchased by New York State Common Retirement Fund
The New York State Common Retirement Fund has increased its stake in Twist Bioscience Corporation (NASDAQ:TWST) by 14.0% in the third quarter, now owning 584,694 shares valued at over $16.45 million. Despite this institutional buying, the company's insiders have sold shares, and Twist Bioscience missed its EPS consensus in the last quarter. Analysts maintain a "Moderate Buy" rating with an average price target of $44.67.
TWIST BIOSCIENCE CORP (NASDAQ:TWST) Reports Mixed Q1 FY2026 Results with Revenue Beat and Wider Loss
Twist Bioscience Corporation (NASDAQ:TWST) reported mixed results for Q1 FY2026, beating revenue estimates with $103.7 million but posting a wider-than-expected loss of $0.50 per share. Despite the loss, the stock saw a positive pre-market reaction, indicating investor focus on revenue execution and business strategy. The company did not provide forward-looking guidance, making the upcoming conference call crucial for management's commentary on performance and strategic direction.
Twist Bioscience Announces Fiscal 2026 First Quarter Financial Results
Twist Bioscience Corporation announced its financial results and business highlights for the first quarter of fiscal year 2026, which ended on December 31, 2025. The company will host a conference call and live audio webcast to discuss these results and provide business updates. Investors and analysts can access the detailed earnings report and investor presentation on the company's Investor Relations website.
Universal Beteiligungs und Servicegesellschaft mbH Boosts Holdings in Twist Bioscience Corporation $TWST
Universal Beteiligungs und Servicegesellschaft mbH significantly increased its stake in Twist Bioscience Corporation ($TWST) by 822.2% in Q3, now holding 65,590 shares valued at approximately $1.85 million. This boost makes up about 0.11% of the company. The article also details other institutional investor activities, recent stock performance, analyst ratings, and insider trading information for Twist Bioscience.
Oligonucleotide Pool Library market Valuation Expected to Hit
The global Oligonucleotide Pool Library Market is projected to reach USD 3.40 billion by 2032, growing at a CAGR of 13.5% from 2026. This growth is driven by AI and machine learning advancements optimizing sequence design and library complexity, alongside rising adoption of CRISPR screening and functional genomics. Key players include Agilent Technologies, Twist Bioscience Corporation, and Integrated DNA Technologies.
